Document:

ex10-66.htm

Exhibit 10.66

 

FORBEARANCE AGREEMENT

THIS FORBEARANCE AGREEMENT  (this “Agreement”) is made as of December 8, 2010, by and among UNIGENE LABORATORIES, INC., a Delaware corporation (“Borrower”), VICTORY PARK MANAGEMENT, LLC, a Delaware limited liability company, as collateral agent and administrative agent (“Agent”) for the benefit of all Secured Parties (as defined in the Security Agreement), and the Secured Parties.  Unless otherwise defined herein, capitalized terms used herein shall have the meanings ascribed to them in the Financing Agreement (as defined below).

W I T N E S S E T H:

WHEREAS, Agent, Borrower and the persons from time to time party thereto as Lenders are party to that certain Amended and Restated Financing Agreement dated as of March 16, 2010 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Financing Agreement”), pursuant to which, among other things, such Lenders made certain loans and other financial accommodations to Borrower, subject to the terms and conditions set forth therein;

WHEREAS, Borrower executed and/or delivered various agreements, documents and instruments in connection with the Financing Agreement, including but not limited to, the Transaction Documents;

WHEREAS, Borrower and GlaxoSmithKline LLC, formerly known as SmithKline Beecham Corporation, a Delaware limited liability company (“GSK”), entered into that certain License Agreement, dated as of April 13, 2002, as the same was amended from time to time (the  “SmithKline License Agreement”), which provided for the exclusive license grant from Borrower to GSK to discover, develop, make, have made, market, sell and import certain Licensed Products (as defined therein) throughout the world;

 

WHEREAS, on the effective date of this Agreement, GSK and Borrower have amended and restated the SmithKline License Agreement (the “Amended SmithKline License Agreement”) to provide, among other things, for Borrower to conduct the Phase II Development Plan, all as more particularly provided therein;

 

WHEREAS, in connection with the execution and delivery of the Amended SmithKline License Agreement, GSK has requested that  Agent and the Secured Parties  forbear, during the Forbearance Period (as defined below), from exercising any of their rights and remedies with respect to any future Event of Default arising as a result of Borrower's breach of either of the financial covenants contained in Sections 8.1(a) and (b) of the Financing Agreement (together, the “Financial Covenants Event of Default”, it being agreed to and understood that a future Event of Default in respect of Section 8.1(a) of the Financing Agreement means a breach of such covenant that first arises on or after the date of this Agreement and a future Event of Default in respect of Section 8.1(b) of the Financing Agreement means a breach of such covenant that first arises for any measurement period ending December 31, 2010 or thereafter), on and subject to the terms and conditions set forth in this Agreement; and

 

  

  

  

WHEREAS, in connection therewith,  Agent and the Secured Parties have agreed to so forbear from exercising any of their rights and remedies with respect to the Financial Covenants Event of Default during the Forbearance Period, on and subject to the terms and conditions set forth in this Agreement,  without constituting a novation;

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged, each of the undersigned hereby agrees as follows:

1.            Modifications to the Transaction Documents.  All references in the Transaction Documents to the “Financing Agreement” (or words of similar import) shall refer to, and for all purposes shall be deemed and construed to refer to, the Financing Agreement, as amended or modified  hereby.

2.           Forbearance and Other Agreements.

(a)           Except as otherwise set forth in Sections 2(b), (c), (d) and (e) below, Agent and each of the Secured Parties hereby agree that, upon the occurrence and during the continuation of a Financial Covenants Event of Default (but solely with respect to such Financial Covenants Event of Default), each shall forbear from the enforcement of its rights and remedies solely with respect to such Financial Covenants Event of Default for the duration of the Forbearance Period.  The term “Forbearance Period” shall mean the time period beginning on the effective date of the Amended SmithKline License Agreement and expiring upon the earliest to occur of (i) the completion of the Phase II Development Plan (as may be deemed to have occurred in accordance with the terms of the Amended SmithKline License Agreement), (ii) termination of the Amended SmithKline License Agreement, (iii) June 30, 2012 (or such later date as the parties hereto may agree in writing), (iv) GSK’s failure to pay the required amount for the Borrower’s achievement of Milestone 5 set forth in Section 3.2(a) of the Amended SmithKline License Agreement in accordance with the terms thereof as in effect on the date hereof, or (v) the date Borrower repudiates or asserts a defense to any obligation or liability under this Agreement or any Transaction Document or makes or pursues a claim against Agent or any Secured Party.  Nothing contained in this Agreement, however, shall limit or restrict Agent or the Secured Parties from taking any action that they may take under the Transaction Documents or at law or in equity (i) necessary or appropriate in their sole discretion to preserve, protect or defend any of the Collateral described in the Transaction Documents or (ii) as a result of the occurrence and continuance of any Event of Default other than the Financial Covenants Event of Default (including, without limitation, exercising all rights and remedies under the Transaction Documents or at law or in equity in respect thereof), whether same first arose prior to the date hereof, or arises during or after the Forbearance Period.  Upon the termination or expiration of the Forbearance Period, (i) the Forbearance Period shall automatically end without the requirement for further action or notice by or on behalf of Agent and the Secured Parties and (ii) Agent and the Secured Parties may elect to commence and/or resume the exercise of their rights and remedies under the Transaction Documents, at law or in equity, with respect to all Financial Covenants Event of Default then in existence, without any further obligation to provide any notice, demand or cure periods unless otherwise required by the Transaction Documents.

 

  

  

  

(b)           Notwithstanding anything to the contrary contained herein, Agent and Secured Parties hereby reserve the right to elect to institute interest at the Default Rate in accordance with subsection 2.2(c) of the Financing Agreement as a result of the occurrence and continuance of any Event of Default, including, without limitation, any Financial Covenants Event of Default.

(c)           Borrower hereby agrees and acknowledges that, the implementation of the Forbearance Period in accordance with the terms hereof notwithstanding, the Financial Covenants Event of Default constitute existing Events of Default for all purposes under the Transaction Documents, including, without limitation, for purposes of determining whether or not certain actions may be taken or otherwise acquiesced to by or on behalf of Borrower (and Borrower agrees that it shall not take any actions or permit any actions to occur to the extent prohibited under the Transaction Documents during the existence of any Event of Default).   Accordingly, any actions taken or omitted by the Borrower in violation of such provisions while any Event of Default exists will constitute additional Events of Default under the Financing  Agreement and the other Transaction Documents.

(d)           Notwithstanding anything to the contrary contained herein, Agent and Secured Parties retain all rights to enforce any term or provision of the Affiliate Subordination Agreement relating to, and all rights and remedies thereunder arising on account of, all Events of Default including any Financial Covenants Event of Default.

(e)           Notwithstanding anything to the contrary contained herein, Agent and Secured Parties retain all rights to enforce any term or provision of the Transaction Documents relating to, and all rights and remedies thereunder arising on account of, all Events of Default including any Financial Covenants Event of Default to the extent such terms, provisions, rights and remedies pertain to the Capital Stock of Borrower.

3.           Reaffirmation.  Borrower hereby acknowledges and agrees that, except as expressly set forth herein, neither this Agreement, nor any actions pursuant to this Agreement, nor any negotiations or discussions among the parties or any of their agents, officers or principals, shall be deemed or construed to cure any existing defaults under the Transaction Documents, or constitute a reinstatement, novation or release of the Notes or the Transaction Documents or an extension of the maturity date of the Notes, or constitute a modification, amendment or waiver of the Notes or the Transaction Documents or a waiver of any Financial Covenants Event of Default.  Borrower hereby (i) ratifies and reaffirms all of its payment and performance obligations, contingent or otherwise, under each Transaction Document to which it is a party, except as expressly modified by this Agreement, and (ii) acknowledges and agrees that such obligations remain in full force and effect, binding on and enforceable against Borrower in accordance with the terms, covenants and conditions of the Transaction Documents, without impairment, except as expressly modified by this Agreement.

4.           Successors and Assigns.  This Agreement shall be binding upon Borrower and Agent, the Lenders, the Holders and the other Secured Parties and each of their respective successors and assigns.  The successors and assigns of such entities shall include, without limitation, their respective receivers, trustees, or debtors-in-possession.

 

  

  

  

5.           Miscellaneous.

(a)           This Agreement, along with the other Transaction Documents, constitutes the entire agreement of the parties with respect to the subject matter hereof and is intended to supersede all prior negotiations, understandings and agreements with respect thereto.  No extension, discharge, termination or waiver of any provision of this Agreement or any consent to any departure therefrom shall be effective unless the same shall be in a writing signed by the party against whom enforcement is sought, and then such waiver or consent shall be effective only in the specific instance, and for the purpose, for which given.  No provision of this Agreement may be modified or amended except by a written agreement specifically referring to this Agreement and signed by the parties hereto.

 

(b)           In the event any provision of this Agreement is held to be invalid, prohibited or unenforceable in any jurisdiction for any reason, then, unless such provision is narrowed by judicial construction, this Agreement shall, as to such jurisdiction, be construed as if such invalid, prohibited or unenforceable provision had been more narrowly drawn so as not to be invalid, prohibited or unenforceable.  If, notwithstanding the foregoing, any provision of this Agreement is held to be invalid, prohibited or unenforceable in any jurisdiction, such provision, as to such jurisdiction, shall be ineffective to the extent of such invalidity, prohibition or unenforceability without invalidating the remaining portion of such provision or the other provisions of this Agreement and without affecting the validity or enforceability of such provision or the other provisions of this Agreement in any other jurisdiction.

 

(d)           Each party shall take such further action and execute and deliver such further documents as may be reasonably necessary or appropriate in order to carry out the provisions and purposes of this Agreement.

 

(e)           All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois.  Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in Chicago, Illinois, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.  Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.

 

  

  

  

 

(f)           This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and, all of which taken together shall constitute one and the same agreement. In the event that any signature is delivered by facsimile transmission or by electronic mail in “portable document format” (or “.pdf”), such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such signature were the original thereof.

 

(g)           Except as modified pursuant hereto, no other changes or modifications to the Financing Agreement and the other Transaction Documents are intended or implied and in all other respects the Financing Agreement and the other Transaction Documents are hereby specifically ratified, restated and confirmed by all parties hereto as of the effective date hereof.  In the event of a conflict between the provisions of this Agreement and the provisions of the Transaction Documents, the provisions of this Agreement shall control.  The Financing Agreement and this Agreement shall be read and construed as one agreement.  Nothing herein shall be deemed to establish a custom or course of dealing between or among the parties hereto.

- Remainder of this page intentionally left blank -

[Signature Pages Follows]

 

  

  

  

 

IN WITNESS WHEREOF, this Agreement has been duly executed by each of the undersigned as of the day and year first set forth above.

 

	 	 
UNIGENE LABORATORIES, INC., a Delaware corporation

	 
	 	 	 	 
	 	
By: 

	/s/ Ashleigh Palmer	 
	 	Name:	Ashleigh Palmer	 
	 	Title:	Chief Executive Officer	 
	 	 	 	 

 

  

  

  

 

	 	 
AGREED as of the date first written above

	 
	 	 	 
	 	 
VICTORY PARK MANAGEMENT, LLC, as Agent

	 
	 	 	 	 
	 	
By: 

	/s/ Matthew Ray	 
	 	Name:	Matthew Ray	 
	 	Title:	Manager	 
	 	 	 	 

 

  

  

  

 

	 	 
AGREED as of the date first written above

	 
	 	 	 
	 	 
Secured Parties:

	 
	 	 	 
	 	 
VICTORY PARK CREDIT OPPORTUNITIES MASTER FUND, LTD.

	 
	 	 	 	 
	 	By:	Victory Park Capital Advisors, LLC, its investment manager	 
	 	 	 	 
	 	
By: 

	/s/ Scott Zemnick	 
	 	Name:	Scott Zemnick	 
	 	Title:	General Counsel	 
	 	 	 	 

 

	 	 
 
VPC FUND II, L.P.

	 
	 	 	 	 
	 	By:	Victory Park GP II, LLC, it general partner	 
	 	 	 	 
	 	By:	
Jacob Capital, L.L.C., its sole partner member and manager

	 
	 	 	 	 
	 	
By: 

	/s/ Richard Levy	 
	 	Name:	Richard Levy	 
	 	Title:	Sole Member/Managerex10-67.htm

Exhibit 10.67

 

Victory Park Management, LLC

227 W. Monroe Street

Suite 3900

Chicago, Illinois 60606

 

December 8, 2010

 

Unigene Laboratories, Inc.

81 Fulton Street

Boonton, New Jersey 07005

Attention: Warren P. Levy

 

Ladies and Gentlemen:

 

We refer to (i) that certain Amended and Restated Financing Agreement, dated as of March 16, 2010, by and among Unigene Laboratories, Inc. (the “Borrower”), the Lenders identified therein and Victory Park Management, LLC, as administrative and collateral agent (the “Agent”) for the Lenders (as amended, modified or supplemented from time to time, the “Financing Agreement”) and the other Transaction Documents and (ii) that certain Forbearance Agreement of even date herewith by and among Borrower, Agent and the Secured Parties (as defined in the Security Agreement). Capitalized terms used but not defined herein have the meanings given to such terms in the Financing Agreement.

 

In consideration for Agent and Secured Parties entering into the Forbearance Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by each of the parties hereto, each of the parties hereto hereby agrees as follows:

 

1.           The definition of “Maximum Permitted Redemption Amount” set forth in Section 1.1 of the Financing Agreement shall be amended by replacing the amount $13,642,472.50 set forth in clause (i) thereof with the amount $10,642,472.50.

 

2.           To the extent the Borrower receives cash proceeds during the Forbearance Period (as defined in the Forbearance Agreement) on account of (i) a sale of the real property commonly referred to as 110 Little Falls Rd., Fairfield, NJ, (ii) a sale of Borrower’s joint venture interest in the joint venture known as Unigene Biotechnology Co., Ltd., (iii) any tax refund, credit, grant or sale, including without limitation, from the sale of unused New Jersey net operating loss carry forwards or New Jersey research and development tax credits or under the federal Qualifying Therapeutic Discovery Project or (iv) payment of Milestone 5 set forth in Section 3.2(a) of the Amended SmithKline License Agreement Agent and Secured Parties hereby waive the mandatory prepayment required pursuant to Sections 2.3(b)(i) and 2.3(b)(vi), as applicable, with respect thereto; provided, however, that any sale of assets or properties of Borrower must be in compliance with the terms of the Financing Agreement or approved by Agent in its sole discretion.

 

  

  

  

 

3.           Agent shall release its liens on and security interests in and to the assets and properties of Borrower described in paragraph 2 above to the extent same are sold in compliance with all terms and provisions of the Financing Agreement.  If Agent is satisfied in its sole discretion with the terms and provisions of any sale of assets and properties of Borrower described in paragraph 2 above that are not otherwise in compliance with the terms and provisions of the Financing Agreement, Agent is hereby authorized to release its liens on and security interests in and to such assets upon the sale thereof, and Agent agrees to so release such liens and security interests upon consummation of such sale.

 

Except as provided above, the Financing Agreement and other Transaction Documents remain unmodified and in full force and effect. The execution and delivery of this letter agreement shall not be deemed to create a course of dealing or otherwise create any express or implied duty by Agent or Secured Parties.  The Agent and Secured Parties reserve all rights and remedies available to them under the Transaction Documents (except as specifically modified hereby or in the Forbearance Agreement).  This letter agreement shall be governed by, and construed in accordance with, the law of the State of Illinois (without giving effect to conflicts of law principles that would require the application of the laws of a different State). This letter agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.  Signatures to this letter agreement delivered by facsimile or other electronic transmission shall be given full force and effect as original signatures.  This letter agreement is a Transaction Document.

 

 

[Signature Page Follows]

 

  

  

  

 

The parties hereto should indicate their agreement to the foregoing by signing and returning to the Agent a counterpart of this letter agreement.

 

Very truly yours,

 

VICTORY PARK MANAGEMENT, LLC,

 

as Agent

By: /s/ Matthew Ray

Name: Matthew Ray

Title:  Manager

 

AGREED AND ACCEPTED:

 

UNIGENE LABORATORIES, INC.,

as Borrower

 

By: /s/ Ashleigh Palmer

Name: Ashleigh Palmer

Title:  President and CEO

 

VICTORY PARK CREDIT OPPORTUNITIES MASTER FUND, LTD.,

as a Secured Party

By: Victory Park Capital Advisors, LLC, its investment manager

By: /s/ Scott Zemnick

Name: Scott Zemnick

Title: General Counsel

VPC FUND II, L.P.,

as a Secured Party

By: Victory Park GP II, LLC, it general partner

By: Jacob Capital, L.L.C., its sole partner member and manager

By: /s/ Richard Levy                                                                

Name: Richard Levy                   

Title: Sole member/Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}]]